Trading Report: The ProMetic Life Sciences Inc. (PLI) Receives C$4.86 Consensus Target Price from Brokerages

The ProMetic Life Sciences Inc. (PLI) Receives C$4.86 Consensus Target Price from Brokerages

Shares of ProMetic Life Sciences Inc. (TSE:PLI) have been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the stock. Two equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is C$4.86.

PLI has been the topic of several recent analyst reports. BLOOM BURTON&CO reaffirmed a “hold” rating on shares of ProMetic Life Sciences in a report on Thursday, October 13th. Royal Bank Of Canada reissued an “outperform” rating on shares of ProMetic Life Sciences in a report on Thursday, August 25th. Scotiabank reissued an “outperform” rating and set a C$5.00 target price on shares of ProMetic Life Sciences in a report on Thursday, October 13th. TD Securities reissued a “speculative buy” rating and set a C$4.50 target price on shares of ProMetic Life Sciences in a report on Wednesday, September 28th. Finally, CIBC dropped their target price on shares of ProMetic Life Sciences from C$5.00 to C$4.85 in a report on Thursday, August 25th.

Related posts

Leave a Comment